Emerald Health Therapeutics Signs New Licensing Deal with Indena

Emerald Health Therapeutics

In a press release this morning, Emerald Health Therapeutics (TSXV:EMH) (OTCQX:EMHTF) announced a new licensing agreement with Italy's Indena.

The deal could lead to stronger CBD-based therapies at lower costs. Let's check this out.

Emerald Health Therapeutics and Indena

To understand what this news means for EMH, it first helps to know who Indena is and what it does.


The Milan-based company develops and "produces high-quality active principles" taken from plants for use in the pharmaceutical and wellness industries. A major factor in its process is specializing in the body's absorption of these principles. 

Now, Idena has signed an agreement with Emerald Health Therapeutics granting the cannabis company exclusivity rights to use Idena's cannabidiol (CBD) extraction technology in Canada. Importantly, this allows Emerald to use Indena’s leading 'Phytosome' technology in the development of new CBD-based products. 

According to the press release:

"[Indena] is adapting an existing proprietary extraction process to facilitate hemp extraction and will exclusively provide Emerald in Canada with this highly optimized process for extracting and isolating CBD to manufacture cannabinoid-based products." 

In short, Indena will now become the exclusive third-party manufacturing supplier of CBD for EMH, who will use this CBD in certain product lines. 

Phytosome Technology

Indena's proprietary Phytosome is a patented technology and is scientifically validated. Essentially, the Phytosome formulation increases the body's absorption of ingredients, "improving their systemic bioavailability."

>> Green Thumb Industries Up 40% YTD and Signs New Acquisition

Due to their nature, cannabinoids are hard for the body to absorb. But by leveraging this technology, Emerald Health Therapeutics can develop more effective CBD-based products for health. This should lead to more potent CBD-based products, resulting in consumers using less product to achieve even greater relief.

According to Stefano Togni of Indena, Emerald's "medical applications of cannabinoids" aligns well with Indena's "phytochemical research."

If the deal is successful, Emerald Health Therapeutics may have found a way to reduce costs long term.

On the news, EMH stock is down 3.39%, but there are many trading hours left in the day for Emerald Health Therapeutics to turn this around. 

Featured Image: Canva

If You Liked This Article Click To Share